9.37
price up icon1.41%   0.13
after-market Handel nachbörslich: 9.31 -0.06 -0.64%
loading

Viatris Inc Aktie (VTRS) Neueste Nachrichten

pulisher
11:37 AM

Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News

11:37 AM
pulisher
10:48 AM

Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha

10:48 AM
pulisher
08:11 AM

What to Expect From Viatris' Next Quarterly Earnings Report - MSN

08:11 AM
pulisher
07:42 AM

What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com

07:42 AM
pulisher
Jul 22, 2025

What analysts say about Viatris Inc. stockExplosive capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Viatris Inc. a good long term investmentExplosive capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Viatris Inc. stock priceFree Trend-Following Techniques - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN

Jul 22, 2025
pulisher
Jul 21, 2025

Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter

Jul 21, 2025
pulisher
Jul 20, 2025

Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Trend Tracker for (VTRS) - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Why Is Viatris Stock Falling In Pre-market? - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris eye ointment fails late-stage study, shares fall - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com India

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris eye therapy fails to meet late-stage trial goal - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN

Jul 18, 2025
pulisher
Jul 17, 2025

Viatris (VTRS) Receives a Hold from Goldman Sachs - The Globe and Mail

Jul 17, 2025
pulisher
Jul 16, 2025

Hypopituitarism Treatment Market Expansion Supported - openPR.com

Jul 16, 2025
pulisher
Jul 16, 2025

Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Viatris' Canadian Workplace Excellence Fuels Long-Term Resilience in Pharma's Turbulent Landscape - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Viatris Certified as a Great Place to Work® in Canada - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

What makes Viatris Inc. stock price move sharplyFree Premium Stock Market Reports - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

Non-Opioid Patch Market CAGR 6.6 percent overview and leading - openPR.com

Jul 14, 2025
drug_manufacturers_specialty_generic RDY
$14.60
price up icon 1.32%
$133.66
price up icon 0.69%
$305.61
price up icon 2.59%
$15.02
price up icon 0.60%
$73.31
price up icon 1.34%
Kapitalisierung:     |  Volumen (24h):